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Abstract
Background: The obligate intracellular protozoan parasite Toxoplasma gondii infects humans and other
warm-blooded animals and establishes a chronic infection in the central nervous system after invasion. Studies
showing a positive correlation between anti-Toxoplasma antibodies and incidences of brain cancer have led to the
notion that Toxoplasma infections increase the risk of brain cancer. However, molecular events involved in
Toxoplasma induced brain cancers are not well understood.
Presentation of the hypothesis: Toxoplasma gains control of host cell functions including proliferation and
apoptosis by channelizing parasite proteins into the cell cytoplasm and some of the proteins are targeted to the
host nucleus. Recent studies have shown that Toxoplasma is capable of manipulating host micro RNAs (miRNAs),
which play a central role in post-transcriptional regulation of gene expression. Therefore, we hypothesize that
Toxoplasma promotes brain carcinogenesis by altering the host miRNAome using parasitic proteins and/or miRNAs.
Testing the hypothesis: The miRNA expression profiles of brain cancer specimens obtained from patients infected
with Toxoplasma could be analyzed and compared with that of normal tissues as well as brain cancer tissues from
Toxoplasma uninfected individuals to identify dysregulated miRNAs in Toxoplasma-driven brain cancer cells.
Identified miRNAs will be further confirmed by studying cancer related miRNA profiles of the different types of
brain cells before and after Toxoplasma infection using cell lines and experimental animals.
Expected outcome: The miRNAs specifically associated with brain cancers that are caused by Toxoplasma infection
will be identified.
Implications of the hypothesis: Toxoplasma infection may promote initiation and progression of cancer by
modifying the miRNAome in brain cells. If this hypothesis is true, the outcome of this research would lead to the
development of novel biomarkers and therapeutic tools against Toxoplasma driven brain cancers.
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Background
Chronic Toxoplasma gondii infection is one of the most
prevalent parasitic infections in humans worldwide and
nearly one-third of the population has been estimated to
be carrying the parasite [1,2]. Upon entry, T. gondii
transforms into fast replicating tachyzoites and infects
various organs of the body including the central nervous
system (CNS). To evade host immune response, some of
the tachyzoites differentiate in to bradyzoites, which are
slow growing and form tissue cysts in the brain [3,4].
During chronic infection, T.gondii tissue-cysts persist for
lifetime of the host without provoking any host immune
attack [5].
Host cell invasion is an active process which is essential
for survival and replication of parasites. While invading a
host cell, T. gondii discharges proteins from its secretory
organelles which include micronemes, rhoptries, and
dense granules. Detection of parasitic proteins with kinase
and phosphatase domains in the host nucleus suggests
that the parasite modulates the host cell signaling and
gene expression [6]. This notion is further supported by a
recent finding that Toxoplasma infection orchestrates the
expression of host miRNAs which are deliberated as the
key regulators of signaling pathways [7].
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http://www.infectagentscancer.com/content/8/1/8MicroRNAs (miRNAs) are short (19–24 nucleotides)
non-protein coding RNAs endogenously regulate gene
expression at the post-transcriptional level by binding
with target mRNAs that trigger their degradation and/or
translational inhibition. A single miRNA can regulate
multiple mRNAs; therefore, miRNAs have imperative
effects on cell signaling networks [8,9]. Several studies
have identified differential expression of miRNAs in
brain tumors including glioblastoma, pituitary adenoma,
and medulloblastoma when compared to normal tissues
[10,11]. The miRNAs play a critical role in brain car-
cinogenesis and metastasis by acting as either oncogenes
or tumor suppressors [12].
Toxoplasma is an important non-viral pathogen shown
to be associated with the occurrence of brain tumors.
Previous investigations have revealed that T. gondii
could cause gliomas in experimental animals [13]. Stud-
ies carried out by Ryan et. al., [14] showed that antibody
positivity to Toxoplasma is associated with meningioma.
An epidemiological study analyzing data from 37 coun-
tries for the incidences of adult brain cancers and
Toxoplasma infected people associated a nearly two-fold
increase in the risk of brain cancers across the range of
prevalence in Toxoplasma infection [15]. These studies,
though correlational, suggest that Toxoplasma should be
investigated further as a possible oncogenic pathogen in
humans. A recent work conducted in France showed
that mortality rates due to brain cancer correlated posi-
tively with the local sero-prevalence of Toxoplasma,
particularly in the people who are 55 years of age or
older [16]. Despite these strong evidences suggesting
that Toxoplasma is associated with brain cancer, it is
unclear how the infection causes this debilitating cancer
in humans. In this article, we present a hypothesis that
Toxoplasma infection may have the ability to modulate
the host miRNAs and could potentially promote the de-
velopment of brain cancer.
Presentation of the hypothesis
Toxoplasma has an inherent ability to manipulate host
cell signaling pathways and processes by interfering with
the global gene expression profiles of the invaded cells
[6,17]. Microarray analysis showed that more than 1,000
host cell genes involved in the various processes includ-
ing apoptosis, inflammation, metabolism, cell growth
and differentiation, are up-regulated or down-regulated
after the Toxoplasma invasion [18-20]. During intracel-
lular infections, the host cell responds by initiating apop-
totic response which reduces survival and proliferation
of the parasites and makes the parasites susceptible to
immune attack. However, Toxoplasma has established
several strategies to neutralize the extrinsic and intrinsic
cellular suicide programs of the infected cells [6,21].
Invasion of Toxoplasma turns host cells resistant to
multiple inducers of apoptosis, including Fas-dependent
and Fas-independent CTL-mediated cytotoxicity, IL-2
deprivation, gamma irradiation, UV irradiation, and cal-
cium ionophorebeauvericin [22]. Toxoplasma exerts
different anti-apoptotic mechanisms for the successful
establishment in different cell types [6,21,22]. Toxo-
plasma significantly reduces Fas/CD95-triggered apop-
tosis by impairing activation of the initiator caspase 8 in
type I cells [23]. While in type II cells, Toxoplasma tar-
gets activation of the pro-apoptotic Bax and Bak to
inhibit the apoptogenic function of mitochondria [24].
Toxoplasma infection has been shown to promote the
expression of anti-apoptotic proteins: Bcl2, Bfl1, Bcl-Xl,
Bcl-w, Mcl-1, Bad and Bax in host cells [25-27].
Toxoplasma also modulates several cell signaling path-
ways including AKT and Phosphoinositide 3-kinases
(PI3Ks) pathways [28,29].
In a search to identify the parasite effector molecules,
proteins of rhoptry and dense granule secretory orga-
nelles were found to be secreted by the parasite during
the invasion, that are capable of modulating host signa-
ling pathways [6]. Interestingly, recent studies showed
that miRNAs, which are important regulators of gene
expression, are manipulated by Toxoplasma to interfere
with the host cell functioning [7,30]. In addition, Toxo-
plasma infection has been shown to specifically increase
levels of mature miR-17-92 derived miRNAs in primary
human foreskin fibroblasts [7]. Toxoplasma dependent
up-regulation of the miR-17-92 promoter is at least
partly responsible for this increase.
The miR-17-92 cluster is associated with brain cancers
[31,32]. Primary human astrocyticglioma tissue speci-
mens are found to be over-expressing the miR-17-92
cluster, compared to non-neoplastic brain control tissues
[31]. Inhibition of the miR-17-92 results in reduced cell
viability and cell proliferation and increased apoptotic
rates [33]. Furthermore, expression analysis of 90
primary human medulloblastomas revealed that compo-
nents of the miR-17-92 polycistron are greatly up-
regulated miRNAs in the most common malignant
pediatric brain tumor, which is medulloblastoma, and
miR-17-92 expression correlates with high levels of
MYC family proto-oncogenes. Besides, expression ana-
lysis of the miR-17-92 cluster showed that three miR-
NAs (miR-92, miR-19a, and miR-20) are over-expressed
only in human medulloblastomas with a constitutively
activated Sonic Hedgehog/patched (SHH/PTCH) signa-
ling pathway, suggesting the role of the miR-17-92 clus-
ter in the formation of aberrant SHH/PTCH pathway
driven medulloblastomas [32]. Molecular targets of
miR-17-92 are found to be CDKN1A, BCL2L11, PTEN
and E2F1; and depletion of miR-17-92 results in the
derepression of CDKN1A and E2F1 at the mRNA level
and of E2F1 and PTEN at the protein level [31]. Since
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http://www.infectagentscancer.com/content/8/1/8Figure 1 Schematic illustration of the hypothesis that Toxoplasma infection alters miRNA pathway leading to brain carcinogenesis.
The miRNA synthesis pathway is mediated by multiple protein complexes that sequentially cleave, export and incorporate miRNA into the
silencing machinery. miRNA is transcribed by RNA polymerase II or III and this pri-miRNA is processed by Drosha–DGCR8 (Pasha) complex to pre-
miRNA, which is exported from the nucleus by Exportin-5 to the cytoplasm. The RNase Dicer is associated with the double-stranded RNA-binding
protein TRBP and the PKR activator PACT processes the pre-miRNA hairpin to 22-nt miRNA duplexes. One strand of mature miRNA is loaded into
the RNA-induced silencing complex (RISC) along with Argonaute (Ago2) proteins and it directs RISC to silence target mRNAs through mRNA
cleavage or translational repression while the complementary strand is degraded. This pathway is tightly regulated at transcriptional and post
transcriptional level. The miRNA stability and post translational modifications are used to modulate the functionality of the miRNAs. Proteins of
miRNA processing complexes also play a crucial role in regulating the miRNA processing pathway. We hypothesize that effector molecules
released by Toxoplasma into the host cell may interfere with miRNA synthesis and maturation pathway, which in turn modulate host cell survival
or death signaling pathways.
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http://www.infectagentscancer.com/content/8/1/8the AKT pathway has been shown to be activated by
Toxoplasma infection [6], an interesting possibility is
that miR-17-92 mediated decrease in levels of PTEN
during Toxoplasma infection in brain cells could be acti-
vating AKT pathways which may result in the develop-
ment of brain cancer.
In addition to miR-17-92, various other miRNAs are
critically involved in development and progression of
different types of brain cancers [11,34]. Glioblastoma-
multiforme (GBM), the most common and aggressive
primary intracranial malignancy of brain tumors, is
shown to be associated with up-regulation of miR-221
and down-regulation of miR-128, miR-181a, miR-181b,
and miR-181c [35]. Another miRNA elevated in GBM is
miR-21, which regulates multiple genes associated with
cancer cell proliferation, such as, apoptosis, and inva-
siveness [36]. Also, miR-21 is up-regulated in medullo-
blastoma cells and its down-regulation increased the
expression of negative modulators of cancer cell migra-
tion, E-Cadherin and TIMP2 proteins and their positive
regulator PDCD4 which results in decreased motility of
medulloblastoma [37,38]. Pituitary adenomas are the
most common tumors of the central nervous system and
show differential expression of 30 miRNAs including
tumor suppressors belonging to the let-7 family, com-
pared to normal pituitary gland [39].
Furthermore, the Toxoplasma genome codes for
ostentatious RNA silencing machinery and endoge-
nous small silencing RNAs, including miRNAs [40].
Toxoplasma may be using its own miRNAs to modify
host cell functions, analogous to some mammalian
viruses encoding their own miRNAs [41]. In view of
above findings, we hypothesize that Toxoplasma asso-
ciated miRNA dysregulation may be playing a central
role in the development of brain carcinogenesis, consi-
dering the significance of miRNAs in brain tumor deve-
lopment and progression [Figure 1].
To our knowledge, there is only one study that utilized
primary human foreskin fibroblasts to elucidate the
effect of Toxoplasma infection on the host cell miRNAs
[7]. However, the host miRNAs regulated by Toxplasma
may vary based on cell type. Thus the possibility that
Toxoplamsa infection can alter expression of several
other miRNAs along with miR-17-92 in different types
Figure 2 Experimental approach validating the hypothesis. Flowchart of suggested procedures required to identify and validate miRNAs
associated with Toxoplasma-mediated brain cancers. Aberrantly expressed miRNAs will be identified by analyzing miRNA expression profiles of
specimens obtained from Toxoplasma infected brain cancer patients in comparison to the uninfected brain cancer specimens and specimens
from normal individuals. The identified miRNAs will be further validated in brain cell lines and animal models by experimental Toxoplasma
infection. Functional analyses will be helpful to identify miRNAs and their potential targets that regulate host signaling pathways. Thus,
identification and validation of miRNAs will lead to the development of biomarkers and therapeutics for Toxoplasma associated brain cancers.
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tial to study miRNA profiles of various types of Toxo-
plasma positive brain cancer cells; especially GBM or
medulloblastoma, the most prevalent brain cancers.
Testing the hypothesis
To test this hypothesis, miRNA profiles of normal brain
and cancer tissues collected from brain cancer patients
with and without Toxoplasma infection will be first
studied. The details of the study have been summarized
in Figure 2. Frozen, fresh or formalin-fixed paraffin-
embedded brain tissues will be obtained from brain
banks and hospitals performing brain surgeries and
examined by pathologists, assessing the presence of
Toxoplasma infection and the proportion of normal and
tumor cells. Commercially available reagents containing
concentrated chaotropic salts, such as guanidiniumthio-
cyanate (e.g., Trizol) followed by silica column extraction
will be used to extract high quality miRNA from brain
tissue samples. Three major approaches are now com-
monly used for miRNA profiling: quantitative reverse
transcription PCR (qRT-PCR), microarrays and high-
throughput RNA sequencing. Additional new methods
are emerging which will be applied for miRNA profiling
in the future [42]. High throughput microarray techno-
logy will be used to identify miRNA signatures asso-
ciated with Toxoplasma infected brain cancer cells. The
identified global miRNAs profile will be further validated
by qRT-PCR in different brain cell lines and brain cells
of experimental animals before and after Toxoplasma
infection. In addition, brains of the animals chronically
infected with Toxoplasma will be monitored in vivo for
malignant transformation and tumor growth using
neuroimaging techniques [43,44]. The miRNAs that are
differentially expressed in Toxoplasma driven brain
cancer cells could be used as markers to classify these
cancers. As briefly outlined, in Figure 2, functional
analysis of identified miRNAs by over expression and
down regulation in cell lines and experimental
animals will reveal the effect of Toxoplasma-modified
m i R N Ae x p r e s s i o no ns u r v i v a la n dd e a t hp a t h w a y s
of brain cancer cells. Thus, these studies could be
very useful in the development of miRNA-based
therapeutics.
Implications of the hypothesis
Decades of Toxoplasma research has made us aware of
the parasite’s ability to manipulate host cell signaling
pathways. Though some parasite proteins were identified
as effector molecules for this function, the underlying
molecular mechanisms of Toxoplasma- mediated brain
carcinogenesis are not clearly understood. Our hypo-
thesis predicts that Toxoplasma-modified miRNAs may
play a critical role in initiation and progression of brain
carcinogenesis, though the outcome of the infection pos-
sibly depends on the mode of infection, parasitic strain,
type of host cell and miRNA expression patterns of host
cell and parasite proteins. If our hypothesis is true, miR-
NAs critically involved in the Toxoplasma driven cancers
could be identified and they could be utilized as novel
diagnostic and therapeutic targets. Thus, further re-
search on the specific miRNA pathways affected by
Toxoplasma in various brain cells would open new
avenues in the diagnosis and treatment of brain cancers
caused by Toxoplasma infection.
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